Biologics in Primary Care: What You Need to Know

Biologic therapies have transformed the management of chronic inflammatory and autoimmune conditions, yet their complexity often poses challenges in primary care. This session will review the mechanisms of action, therapeutic targets, and delivery methods of commonly used biologics. Attendees will learn to identify key indications and safety concerns relevant to primary care practice, including infection risk, immunization considerations, and risk for paradoxical reactions. This presentation will also emphasize the critical role of primary care clinicians in coordinating care with specialists, managing comorbidities, monitoring for adverse effects, and supporting treatment adherence. Practical strategies and case examples will help clinicians integrate these responsibilities into routine practice to optimize patient outcomes.

CME/CE Information

1.00 AMA PRA Category 1 Credits™ or 1.00 AANP, including 1.00 AANP Pharm

Release Date: 5/7/2026

Expiration Date: 6/28/2026

Topics

Learning Objectives

Review the mechanism of action, therapeutic targets, and modes of delivery of common biologic therapies
Identify the indications and key safety concerns of biologic therapies commonly seen in primary care practice
Discuss the role of primary care clinicians in coordinating care, managing comorbid conditions, monitoring for side effects including autoimmune/paradoxical effects, and contributing to the success of the treatment

Faculty

Vani Potluri, MD, DABOM

Assistant Professor of Medicine, Section of General Internal Medicine, Baylor College of Medicine, Houston, Texas

Learn More

Jaime J. Rueda, MD

Assistant Professor, Department of Internal Medicine, Baylor College of Medicine

Associate Program Director, Internal Medicine-Pediatrics Residency Program, Baylor College of Medicine

Martin Luther King, Jr Health Center Internal Medicine Pediatrics Residency Continuity Clinic Director

Learn More

Disclosures

The following relevant financial relationships have been disclosed by those in a position to influence the content of this activity. All have been mitigated by Pri-Med Institute:

Richard Hamill, MD (Moderator): Researcher for Pfizer

All other planners and faculty involved in this activity have disclosed no relevant financial relationships.

CME/CE Information

AMA PRA Category 1 Credits™

Accreditation Statement

Pri-Med Institute is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Designation Statement

Pri-Med Institute designates this enduring material for a maximum of 1.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

AANP

Accreditation Statement

This activity has been planned and implemented in accordance with the Accreditation Standards of the American Association of Nurse Practitioners^® (AANP) through the joint providership of Pri-Med Institute and Baylor College of Medicine. Pri-Med Institute is accredited by the AANP as an approved provider of nurse practitioner continuing education. Provider Number 040308.

Designation Statement

This activity is approved for 1.00 contact hour, which includes 1.00 hour of pharmacology.

Fine Print

Computer System Requirements

The preferred browser is Google Chrome. If using a different browser, such as Safari, Firefox or Edge, make sure you are using the most up-to-date version. Your Internet settings should be set to accept cookies and JavaScript. If cookies and/or JavaScript are disabled, the site may not function properly. A high-speed Internet connection is not required; however, it is recommended for faster download times.

Disclaimer

The opinions, ideas, and recommendations expressed in this educational activity are those of the faculty only and are not necessarily endorsed by, nor do they necessarily reflect, those of their affiliated institutions, Pri-Med Institute, Pri-Med Institute Advisory Boards and Consultants, DBC Pri-Med, LLC.

Clinical judgment must guide each clinician in weighing the possible risks, benefits, or contraindications of any diagnostics, interventions or treatments discussed. Clinicians should review manufacturers’ product information and consider these with the recommendations of other authorities when applying the assessment and/or clinical management strategies discussed in this activity to the care of their patients.

Statement of Independence

Pri-Med Institute educational activities are developed and conducted in accordance with the ACCME's Standards for Integrity and Independence in Accredited Continuing Education. It is the mission of Pri-Med Institute to develop and present educational activities that are timely, fair-balanced, scientifically rigorous, and that serve to improve patient outcomes. To that end, we welcome your comments about how to better serve your needs.

Disclosure Policies and Contacting Pri-Med Institute

Pri-Med Institute Accredited Provider
Pri-Med programs are owned and operated by DBC Pri-Med, LLC, a division of Diversified Communications, Inc. Pri-Med Institute, the accredited division of Pri-Med, is accredited with commendation by the ACCME and approved as a provider of continuing education by the AANP.

Disclosures and Conflict of Interest
Pri-Med Institute requires all individuals in a position to influence educational content for Pri-Med Institute-certified CME/CE activities to disclose personal financial relationships with commercial interests or ineligible companies prior to contributing to its educational activities. Pri-Med Institute assesses disclosed relationships and follows a defined process to mitigate real or implied conflicts to ensure, to the best of its ability, that all educational content is free of commercial bias. All relevant financial relationships have been mitigated Financial disclosures for everyone in control of educational content are provided before the start of each CME/CE activity.

Discussion of Off-Label Uses and Investigational Products
During the course of their presentations, the faculty may mention uses of products that have not been approved in the United States for the indication(s) being discussed. All presenters are instructed to notify participants when they are discussing unapproved uses or investigational agents. In addition, specific slides will include notation of the off-label use or investigational agent being discussed. Views presented related to unapproved uses of products are solely those of the presenter(s) and are not endorsed by Pri-Med Institute or DBC Pri-Med, LLC.

Questions? If you have questions about this activity, please email support@pri-med.com or call (877) 477-4633.